NMDAE: Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
Placebo Cap: Use of placebo as a comparator
Study summary
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Have a DSM-5 (American Psychiatric Association) diagnosis of MDD
* Have failed to respond to at least one antidepressant with adequate dosage and treatment duration
* Their original treatments should have been unchanged for at least 8 weeks. Some treatment-resistant patients (that is, having failed to respond to at least two different classes of antidepressants) who have started to refuse any antidepressant by themselves due to previous failure experience are also allowed, if they have already been antidepressant-free for at least 2 weeks
* 17-item Hamilton Rating Scale for Depression total score ≥ 18
* Agree to participate in the study and provide informed consent
Exclusion Criteria:
* Current substance abuse or history of substance dependence in the past 6 months
* History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study
* Bipolar disorder, schizophrenia or other psychotic disorder
* Moderate-severe suicidal risks
* Severe cognitive impairment
* Initiating or stopping formal psychotherapy within six weeks prior to enrollment
* A history of previously received electroconvulsive therapy
* Inability to follow protocol
Primary outcome measure(s)
Change in Hamilton Rating Scale for Depression — week 0, 2, 4, 6, 8 Assessment of depressive symptoms Minimum value: 0, maximum value:52, the higher scores mean a worse outcome.
Change in Global Assessment of Functioning — Week 0, 2, 4, 6, 8 Assessment of global improvement. Minimum value: 1, maximum value:100, the higher scores mean a better outcome.
Trial sites (1)
Facility
City
Region
Status
Department of Psychiatry, China Medical University Hospital
Taichung
Taiwan
Recruiting
More China Medical University Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.